CIBC Private Wealth Group’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$11.5M Sell
462,326
-20,873
-4% -$526K 0.02% 334
2025
Q3
$12.3M Sell
483,199
-421,571
-47% -$10.4M 0.02% 322
2025
Q2
$21.9M Sell
904,770
-157,136
-15% -$3.66M 0.04% 271
2025
Q1
$23.2M Buy
1,061,906
+83,274
+9% +$2.18M 0.05% 239
2024
Q4
$26.3M Sell
978,632
-319,361
-25% -$8.66M 0.05% 241
2024
Q3
$37.6M Buy
1,297,993
+19,253
+2% +$562K 0.07% 212
2024
Q2
$35.7M Sell
1,278,740
-131,548
-9% -$3.62M 0.07% 203
2024
Q1
$39.1M Buy
1,410,288
+48,991
+4% +$1.36M 0.08% 196
2023
Q4
$39.2M Sell
1,361,297
-2,522,877
-65% -$76.3M 0.08% 195
2023
Q3
$129M Sell
3,884,174
-15,783
-0.4% -$558K 0.3% 83
2023
Q2
$143M Buy
3,899,957
+2,566,424
+192% +$99.9M 0.31% 83
2023
Q1
$146M Buy
1,333,533
+38,550
+3% +$1.66M 0.32% 75
2022
Q4
$52.4M Sell
1,294,983
-3,788
-0.3% -$182K 0.18% 99
2022
Q3
$56.8M Buy
1,298,771
+2,000
+0.2% +$97.2K 0.15% 134
2022
Q2
$68M Sell
1,296,771
-46,949
-3% -$2.39M 0.18% 123
2022
Q1
$69.6M Buy
1,343,720
+179,268
+15% +$9.3M 0.15% 130
2021
Q4
$68.8M Buy
1,164,452
+84,902
+8% +$4.21M 0.14% 135
2021
Q3
$46.4M Sell
1,079,550
-75,138
-7% -$3.33M 0.11% 152
2021
Q2
$45.2M Sell
1,154,688
-78,510
-6% -$3.05M 0.1% 159
2021
Q1
$44.7M Buy
1,233,198
+132,321
+12% +$4.7M 0.11% 156
2020
Q4
$40.5M Buy
1,100,877
+16,252
+1% +$596K 0.11% 153
2020
Q3
$37.4M Buy
1,084,625
+361,115
+50% +$12.7M 0.11% 147
2020
Q2
$22.4M Sell
723,510
-368,162
-34% -$12.5M 0.11% 138
2020
Q1
$33.8M Buy
1,091,672
+25,012
+2% +$852K 0.15% 133
2019
Q4
$39.6M Sell
1,066,660
-296
-0% -$10.5K 0.13% 143
2019
Q3
$36.4M Sell
1,066,956
-111,215
-9% -$4.04M 0.13% 146
2019
Q2
$48.4M Sell
1,178,171
-35,491
-3% -$1.41M 0.17% 131
2019
Q1
$48.9M Buy
1,213,662
+42,627
+4% +$1.71M 0.19% 131
2018
Q4
$48.5M Sell
1,171,035
-10,981
-0.9% -$456K 0.22% 123
2018
Q3
$49.4M Sell
1,182,016
-9,240
-0.8% -$356K 0.19% 138
2018
Q2
$41M Sell
1,191,256
-24,634
-2% -$842K 0.17% 142
2018
Q1
$40.9M Sell
1,215,890
-51,271
-4% -$1.76M 0.18% 140
2017
Q4
$43.5M Buy
1,267,161
+8,982
+0.7% +$306K 0.18% 140
2017
Q3
$42.6M Buy
1,258,179
+395,719
+46% +$12.7M 0.19% 138
2017
Q2
$27.5M Sell
862,460
-20,624
-2% -$650K 0.17% 117
2017
Q1
$28.7M Sell
883,084
-30,384
-3% -$958K 0.18% 117
2016
Q4
$28.1M Sell
913,468
-34,954
-4% -$1.07M 0.19% 112
2016
Q3
$30.5M Sell
948,422
-3,946
-0.4% -$132K 0.21% 103
2016
Q2
$31.8M Sell
952,368
-18,875
-2% -$602K 0.23% 102
2016
Q1
$27.3M Buy
971,243
+9,064
+0.9% +$259K 0.21% 104
2015
Q4
$29.5M Sell
962,179
-28,880
-3% -$909K 0.23% 104
2015
Q3
$29.5M Sell
991,059
-5,750
-0.6% -$184K 0.24% 99
2015
Q2
$31.7M Sell
996,809
-13,826
-1% -$451K 0.23% 96
2015
Q1
$33.4M Buy
1,010,635
+1,724
+0.2% +$54.8K 0.25% 96
2014
Q4
$29.8M Buy
1,008,911
+9,247
+0.9% +$265K 0.23% 103
2014
Q3
$28M Sell
999,664
-264,032
-21% -$7.41M 0.22% 107
2014
Q2
$35.6M Sell
1,263,696
-274,438
-18% -$7.82M 0.29% 99
2014
Q1
$47.1M Buy
+1,538,134
New +$45.9M 0.4% 86

Other funds holding PFE

CIBC Private Wealth Group's PFE Position: Q4 2025 in Review

CIBC Private Wealth Group reduced its Pfizer (PFE) stake by 4.3% in Q4 2025, selling an estimated $526K and leaving 462,326 shares worth $11.5M. The position accounts for 0.02% of the portfolio, ranked #334.

CIBC Private Wealth Group first reported a position in PFE in Q1 2014 and has held it in 48 quarters since. The position peaked at $146M in Q1 2023. 2,905 funds tracked by Wall St. Rank hold PFE as of Q4 2025.

  • CIBC Private Wealth Group held 462,326 shares of Pfizer worth $11.5M as of Q4 2025.
  • CIBC Private Wealth Group sold 20,873 Pfizer shares in Q4 2025, an estimated $526K.
  • Pfizer made up 0.02% of CIBC Private Wealth Group's portfolio in Q4 2025, its #334 holding.
  • CIBC Private Wealth Group first reported a position in Pfizer in Q1 2014 and has held it in 48 quarters since.
  • CIBC Private Wealth Group's Pfizer position peaked at $146M in Q1 2023.
  • 2,905 funds tracked by Wall St. Rank held Pfizer as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.